GeneQuery™ Human Regulation of Cancer Immune Evasion qPCR Array Kit (Plate 1 of 2)

The immune system can effectively recognize cancer cells. However, a hallmark of cancer cells is they acquire the ability to evade immune destruction. The genetic basis for cancer immune evasion remains largely elusive. Cancer immunotherapy, an emerging and effective way to treat many types of cancer, utilizes the ability of the immune system to recognize cancer cells while depriving cancer cells of their immune evasion. ScienCell's GeneQuery™ Human Regulation of Cancer Immune Evasion qPCR Array kits (GQH-CIE1 and GQH-CIE2) are designed to facilitate a better understanding of the mechanisms by which cancer cells evade immune control. The genes selected have been shown to enhance or decrease the resistance of cancer cells to immune control when disrupted. Genes selected are based on genome-wide CRISPR screens^1 , and brief examples of how included genes may be grouped according to their functions are shown below:

• Necroptosis: - FADD, FAS, TNFRSF1A, TRADD, TRAF2, FAS, IRF9, CFLAR, TRPM7, IFNAR1, IFNAR2, IFNGR1, IFNGR2, RBCK1, TNFAIP3, RNF31, VPS4B, CHMP5, VDAC2
• Autophagy: - MAPK1, MAP3K7, CFLAR, BECN1, ATG12, ATG7, ATG5, ATG3, RB1CC1, ATG14, ATG9A, ATG101, BECN1, ATG10, ATG14
• Endocytosis: - TGFBR2, TFRC, ARF6, VPS4B, CHMP5, VPS35, IST1
• TNF signaling: - MAP3K7, FADD, TNFRSF1B, TNFRSF1A, TNFAIP3, TRADD, CFLAR, MAPK1, TAB2, FAS, TRAF2, TAB1, BCL2L1, CREBBP, TBK1, MAPK1, FAS, IRF1
• Interferon signaling: - IFNAR1, IFNGR1, IFNGR2, STAT1, JAK1, JAK2, PTPN2, STAT2, IFNAR2, SOCS1, UBE2N, IRF9, IRF1, TAP1, PSMB9
• NOD-like receptor signaling: - FADD, TRAF2, MAPK1, IRF9, TRPM7, IFNAR1, IFNAR2, ATG12, ATG5, RBCK1, JAK1, TNFAIP3, RNF31, VDAC2, PKN2
• NFKB signaling: - IKBKB, IKBKG, TNFRSF1A, TRADD, TRAF2, TAB1, TAB2, MAP3K7, CFLAR, TNFAIP3
• JAK-STAT signaling: - JAK2, IRF9, SOCS1, IFNAR1, IFNAR2, IFNGR1, IFNGR2, JAK1, STAT1, STAT2, PTPN2, PKN2
• MAPK signaling: - TNFRSF1A, TRADD, TRAF2, MAPK1, TGFBR2, FAS, TAB1, TAB2, MAP3K7, MAPK1, FAS, TAB2, TAB1, PKN2
• IL-17 signaling: - FADD, TRADD, TRAF2, MAPK1, TNFAIP3
• Th17 cell differentiation: - MAPK1, TGFBR2, JAK2, IFNGR1, IFNGR2, JAK1, STAT1
• GPI anchor biosynthesis: - PIGK, PIGS, PIGT, PIGU, GPAA1
• Antigen presentation: - TAP2, B2M, TAP1, CALR, PDIA3, TAPBP
• Ubiquitin mediated proteolysis: - CUL3, UBR5, SOCS1, UBE2N, UBE2G2, RBCK1, ATG7, UFL1
• Protein processing in ER: - UBE2G2, MOGS, PRKCSH, NPLOC4, TRAF2, PDIA3, CALR
• Other innate immunity signaling pathways: - HDAC1, SRSF7, PPP1CA, HCFC2, USP7, ADAR, NXT1, PPP2R2A, PPP2R3C

References - 1. K. A. Lawson et al . Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature - , 586, 120-6 (2020) GeneQuery™ qPCR array kits are qPCR ready in a 96-well plate format, with each well containing one primer set that can specifically recognize and efficiently amplify a target gene's cDNA. The carefully designed primers ensure that: (i) the optimal annealing temperature in qPCR analysis is 65°C (with 2 mM Mg^2+ , and no DMSO); (ii) the primer set recognizes all known transcript variants of target gene, unless otherwise indicated; and (iii) only one gene is amplified. Each primer set has been validated by qPCR with melt curve analysis, and gel electrophoresis.

A hallmark of cancer cells is they acquire the ability to evade immune destruction. ScienCell's GeneQuery™ Human Regulation of Cancer Immune Evasion qPCR Array kits (GQH-CIE1 and GQH-CIE2) are designed to facilitate a better understanding of the mechanisms by which cancer cells evade immune control. The genes selected have been shown to enhance or decrease the resistance of cancer cells to immune control when disrupted.